INVESTOR OVERVIEW

Overview

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases.

Recent News

January 29, 2021 at 8:00 AM EST

▸ Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

November 12, 2020 at 4:10 PM EST

▸ Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

October 26, 2020 at 5:00 PM EDT

▸ Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

IR Contact

Andrea Matthews

Phone: (617) 349-1971

E-mail: [email protected]

Upcoming Events

There are currently no events to display.

The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.